Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab-Reference-Cited by-同舟云学术

Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Published:2019-11-01 Issue:11 Volume:155 Page:1312
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Soria Angèle¹²,Du-Thanh Aurélie³,Seneschal Julien⁴,Jachiet Marie⁵,Staumont-Sallé Delphine⁶⁷,Barbarot Sébastien⁸,

Affiliation:

1. Service de Dermatologie et d’Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France

2. Sorbonne Universités, Paris, Centre d’Immunologie et des Maladies Infectieuses–Paris (Cimi-Paris), INSERM U1135, Paris, France

3. Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France

4. Service de Dermatologie, Hôpital Saint André, Centre de Référence des Maladies Rares de la Peau, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

5. Service de Dermatologie, Hôpital Saint-Louis, Paris, France

6. Centre Hospitalier Universitaire de Lille, Service de Dermatologie et Vénérologie, F-59000 Lille, France,

7. University of Lille, INSERM U995-LIRIC-Lille Inflammation Research International Center, F-59000 Lille, France

8. Centre Hospitalier Universitaire de Nantes, Service de Dermatologie, Nantes, France

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2749354/jamadermatology_soria_2019_ld_190021.pdf

Reference6 articles.

1. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.;Simpson;N Engl J Med,2016

2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.;Blauvelt;Lancet,2017

3. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab.;Zhu;JAMA Dermatol,2019

4. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.;Blauvelt;Br J Dermatol,2019

5. The role of Malassezia in atopic dermatitis affecting the head and neck of adults.;Darabi;J Am Acad Dermatol,2009

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08

2. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study;Archives of Dermatological Research;2024-07-23

3. Fungal Head and Neck Dermatitis: Current Understanding and Management;Clinical Reviews in Allergy & Immunology;2024-07-20

4. Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab;World Allergy Organization Journal;2024-07

5. ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI;Journal of Anatolian Medical Research;2024-06-11